(-0.03%) 5 467.92 points
(-0.35%) 38 976 points
(0.35%) 17 781 points
(0.37%) $81.13
(-3.23%) $2.67
(-0.88%) $2 310.20
(-0.27%) $28.79
(1.61%) $1 002.30
(0.27%) $0.936
(0.71%) $10.68
(0.38%) $0.791
(-0.21%) $87.31
Live Chart Being Loaded With Signals
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy...
Stats | |
---|---|
本日の出来高 | 7 132 |
平均出来高 | 523 414 |
時価総額 | 4.92M |
EPS | $-0.610 ( Q1 | 2024-05-15 ) |
次の収益日 | ( $-0.550 ) 2024-08-12 |
Last Dividend | $18 491 ( 2008-04-23 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.100 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0100 (1.57%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-28 | Dewitt Sheila | Buy | 0 | |
2024-02-22 | Tucker Joseph Edward | Buy | 100 000 | Common Stock |
2024-02-22 | Facchini Peter J. | Buy | 50 000 | Common Stock |
2024-02-22 | Coveney Kevin Michael | Buy | 60 000 | Common Stock |
2023-09-15 | Pasqualone Frank | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 80 transactions |
Buy: 11 099 470 | Sell: 332 443 |
ボリューム 相関
Enveric Biosciences, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Enveric Biosciences, Inc. 相関 - 通貨/商品
Enveric Biosciences, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-408 030 (0.00 %) |
EPS: | $-8.02 |
FY | 2023 |
収益: | $0 |
総利益: | $-408 030 (0.00 %) |
EPS: | $-8.02 |
FY | 2022 |
収益: | $0 |
総利益: | $-435 201 (0.00 %) |
EPS: | $-12.77 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-103.50 |
Financial Reports:
No articles found.
Enveric Biosciences, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $18 491 | 2008-04-23 |
Last Dividend | $18 491 | 2008-04-23 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $18 491 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $18.00 | 0.05% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
23 Apr 2008 | $18 491 | 07 Apr 2008 | 15 Apr 2008 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -23.30 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.704 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.43 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.48 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.88 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.68 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -3 201.70 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.89 | 2.00 | -0.963 | -1.925 | [0 - 30] |
freeCashFlowPerShareTTM | -2.89 | 2.00 | -1.444 | -2.89 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.412 | 1.000 | 6.46 | 6.46 | [0.2 - 0.8] |
operatingProfitMarginTTM | -21.74 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0731 | 0.800 | -2.85 | -2.28 | [0.5 - 2] |
Total Score | -2.97 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.165 | 1.000 | -0.118 | 0 | [1 - 100] |
returnOnEquityTTM | -3.43 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.89 | 2.00 | -0.963 | -2.89 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.89 | 2.00 | -0.963 | -1.925 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00660 | 1.500 | -3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -17.86 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.89 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。